×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Non-Hodgkin Lymphoma

Following a discussion on the multidisciplinary management of Waldenström Macroglobulinemia, Steven P. Treon, MD, PhD, reflects on the future management of this disease.
 
Steven P. Treon, MD, PhD, provides insight on balancing safety and efficacy while treating Waldenström macroglobulinemia with BTK inhibitors.
Key opinion leader Steven P. Treon, MD, PhD, reviews the advent of targeted therapy for patients with Waldenström macroglobulinemia.
 
Moving to the second-line setting and beyond, an expert discusses the importance of sequencing and quality of life in managing Waldenström macroglobulinemia.
Given the advent of targeted therapy, Steven P. Treon, MD, PhD, reflects on how the frontline management of Waldenström macroglobulinemia is changing.
An expert provides his perspective on the historic frontline management of patients with Waldenström macroglobulinemia.
As Waldenström macroglobulinemia does not always merit immediate treatment, Steven P. Treon, MD, PhD, discusses watch-and-wait methodology.
A detailed overview of specific tests and factors that impact the diagnosis and prognosis of Waldenström macroglobulinemia is provided.
 
In light of challenges present in diagnosing Waldenström macroglobulinemia, Steven P. Treon, MD, PhD, discusses what tests and factors are useful in this setting.
A key opinion leader shares which factors indicate risk for developing Waldenström macroglobulinemia.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other